Inhibikase Therapeutics Azioni (NASDAQ: IKT)

Ultime notizie per Inhibikase Therapeutics (NASDAQ:IKT) Azioni

Inhibikase Therapeutics

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics Inc

iTokk Inc

INTERTEK GROUP PLC ORD by Intertek Group Plc

Intertek Group PLC

INTERTEK GROUP UNSP/ADR by Intertek Group Plc

The ONE by ONE Recycling program has collected over 101 million used contact lenses, blister packs and top foils since the program's launch in November 2016. The Biotrue Eye Care Recycling program, which launched in April 2021, has collected over 1.3 million eye drop single dose units, lens cases and lens solution caps, as well as all Biotrue-branded eye drop bottles2. Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.

News

BLCO

Bausch + Lomb's ONE By ONE And Biotrue Eye Care Recycling Programs Collect Over 100M Units Of Used Materials

Janney Montgomery Scott analyst Timothy Coffey upgrades Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) from Neutral to Buy.

Upgrades

Analyst Ratings

BANR

Janney Montgomery Scott Upgrades Banner to Buy

<ul>
<li>AMG to acquire a minority equity interest in Verition, a global multi-strategy investment firm with $12.6 billion in AUM</li>
<li>Verition's management will retain a substantial majority of the firm's equity and continue to lead Verition as an independent firm, in line with AMG's partnership approach</li>
<li>Partnership further diversifies AMG's business and increases its exposure to alternative strategies</li>
</ul>

AMG Acquires Minority Stake In Verition Fund Management, Expanding Alternative Investment Strategies

Creating symmetrical, same-size gold nanospheres in microgravity that could accelerate speed and accuracy of blood tests for cancer, other diseases

Redwire Expands Drug Development In Microgravity With PIL-BOX And New Cancer-Detection Experiment On ISS

Health Care

General

CTSO

CytoSorbents Received $1.7M In Cash Proceeds From The Sale Of Its 2023 And Amended 2022 Net Operating Loss And R&D Tax Credits From The Technology Business Tax Certificate Transfer Program, Sponsored By The New Jersey Economic Development Authority

MLEC

Moolec Science Sa Announced That It Has Entered Into A Business Combination Agreement With Bioceres Group Limited and Other Related Entities In An All-stock Transaction

Earnings

Earnings Beats

HBT Finl Q1 2025 Adj. EPS $0.61 Beats $0.57 Estimate, Sales $58.014M Beat $57.380M Estimate

Biotech

ARVN

Arvinas Announced That New Preclinical Combination Data For ARV-393 Will Be Presented At The American Association For Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>, HKEX: 6855))), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), the company's investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. Olverembatinib, the company's novel next-generation tyrosine kinase inhibitor (TKI), received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, and retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies.
 &nbsp;

AAPG

Ascentage Pharma's Proprietary Novel Drugs Lisaftoclax And Olverembatinib Included In 2025 Chinese Society Of Clinical Oncology Guidelines

WIIM

IVVD

Invivyd shares are trading higher after the company signed a $30 million term loan facility with Silicon Valley Bank.

UTHR

United Therapeutics Announces Series Of Presentations And Sponsored Events At ATS 2025, Highlighting Pulmonary Hypertension And Fibrosis Studies

Financing

Invivyd Signs $30M Term Loan Facility With Silicon Valley Bank

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $1150 to $1200.

Price Target

NFLX

Canaccord Genuity Maintains Buy on Netflix, Raises Price Target to $1200

Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.71 by 5.63 percent. This is a 29.31 percent increase over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $31.76 million which beat the analyst consensus estimate of $31.10 million by 2.13 percent. This is a 10.10 percent increase over sales of $28.84 million the same period last year.

GNTY

Guaranty Bancshares Q1 2025 GAAP EPS $0.75 Beats $0.71 Estimate, Sales $31.76M Beat $31.10M Estimate

Phillips 66 Urges Shareholders To Support Board Nominees In Response To Elliott's Conflicts Of Interest

Management

IMVT

Immunovant Has Appointed Eric Venker (Currently President And COO Of Roivant) Appointed As CEO, And Tiago Girao As CFO As Pete Salzmann Retires As Immunovant CEO And Director

Interim Analysis Of DESTINY-Breast 09 Phase III Trial Showd ENHERTU Plus Ertuzumab Demonstrated Statistically Significant And Clinically Meaningful Improvement In Progression-free Survival vs Taxane, Trastuzumab And Pertuzumab As  1st-Line Treatment For Patients With Her2-positive Metastatic Breast Cancer.

Raymond James analyst Josh Beck downgrades Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) from Strong Buy to Outperform and lowers the price target from $275 to $195.

Downgrades

AMZN

Raymond James Downgrades Amazon.com to Outperform, Lowers Price Target to $195

U.S. Vice President JD Vance arrived in India on Monday for a four-day visit aimed at progressing with bilateral ties and fast-tracking a significant trade deal.
While New Delhi rolled out a cultural welcome, the visit prompted grassroots protests from the All India Kisan Sabha (All India Farmers Union), which fears that the proposed agreement could threaten the livelihoods of Indian farmers.
What Happened: Vance, joined by his wife Usha Vance, their children, and senior U.S. officials is set to conduct meetings with Prime Minister Narendra Modi and make trips to Jaipur and Agra.
On April 18, the AIKS announced its decision to stage protests on April 21 in villages and district headquarters across India with the slogan "Vance Go Back! India Is Not For Sale," with plans for effigy burnings and rallies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
</blockquote></div></figure>

Politics

Global

JD Vance Faces Backlash From All India Farmers Union, Who Say Bilateral Trade Talks Will Undermine Farmers, Warn 'India Is Not For Sale'

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products
REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene&nbsp;Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.
The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions.
 &nbsp;

EVGN

ICL To Acquire Majority Activity Of Evogene's Subsidiary Lavie Bio; Term Not Disclosed

Press Releases

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

Inhibikase Announces Expansion of Senior Leadership Team

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Comments

Inhibikase Therapeutics

Notizie

Ultime notizie per Inhibikase Therapeutics (NASDAQ:IKT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO